A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Henrik Gregersen, Valdas Peceliunas, Kari Remes, Fredrik H. Schjesvold, Niels Abildgaard, Hareth Nahi, Andersen Niels Frost, Annette Juul Vangsted, Tobias Wirenfeldt Klausen, Carsten Helleberg, Kristina Carlson, Ulf Christian Frølund, Per Axelsson, Olga Stromberg, Cecilie Hveding Blimark, Olle Linder, Galina Tsykunova, Anders Waage, Markus Hansson, Nina Gulbrandsen

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article number601
JournalBlood
Volume134
Issue numberSupplement 1
ISSN0006-4971
DOIs
Publication statusPublished - 13. Nov 2019
EventAmerican Society of Hematology: 61st Annual Meeting (ASH) - Orlando, United States
Duration: 7. Dec 201910. Dec 2019

Conference

ConferenceAmerican Society of Hematology: 61st Annual Meeting (ASH)
CountryUnited States
CityOrlando
Period07/12/201910/12/2019

Cite this

Gregersen, H., Peceliunas, V., Remes, K., Schjesvold, F. H., Abildgaard, N., Nahi, H., Niels Frost, A., Vangsted, A. J., Klausen, T. W., Helleberg, C., Carlson, K., Frølund, U. C., Axelsson, P., Stromberg, O., Hveding Blimark, C., Linder, O., Tsykunova, G., Waage, A., Hansson, M., & Gulbrandsen, N. (2019). A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group. Blood, 134(Supplement 1), [601]. https://doi.org/10.1182/blood-2019-122141